

Integrum invites to presentation of Q1 2026/27 results

Mölnadal, Sweden – August 31, 2026 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a live webcast presentation of its interim report for the first quarter 2026/27 on Thursday, September 3, 2026, at 10:00 CEST.

CEO Martin Hillsten will present the report together with CFO Louise Wåhlin. The presentation will be held in Swedish, followed by an opportunity to ask questions.

The webcast can be accessed at:

<https://www.finwire.tv/webcast/integrum/q1-2026/>

The report will be available at:

<https://investors.integrum.se/en/financials/reports>

For further information, please contact:

Louise Wåhlin, CFO

Tel: +46 734 63 73 03

Email: louise.wahlin@integrum.se

Certified Adviser

DNB Carnegie Investment Bank AB (publ)

+46 8-588 685 70

certifiedadviser@dnbcarnegie.se

About Us

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.